The E in ESG: Activity-Based Strategies Can Address Climate Impact Of Clinical Research

A partnership approach is required to reduce greenhouse gas emissions generated by pharma clinical studies. That is the advice in this guest contribution by the Sustainable Healthcare Coalition and Johnson & Johnson’s Janssen company to In Vivo’s rolling series on issues in sustainability for healthcare product manufacturers and providers.

world in hand
• Source: Shutterstock

Pharma companies view clinical trials as playing a big part towards achieving the overriding goal of improving patients’ health. But of late, there has been a collective rise in awareness that our work often has an environmental impact that we can help mitigate.

In the process of serving and supporting patients, the combined healthcare sector produces up to 2.6 billion tons of carbon...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from ESG

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By 

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Infographic: Analyzing The Gap In Women’s Health Care

 

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By 

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.